Temab-A an ADC antiMET good activty in MET+ nonSq pretreted wt and EGFRm NSCLC. But: easy to test biomarker in daily practice? In EGFRm cohort higher activity if we add osimertinib? Is really MET+ a predictive biomarker for Temab-A activity in EGFRm? Brain activity? #ESMO2026
26 views · 0 likes · 0 reposts · 0 replies
FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)
https://esmocongress.esmo.orgPACE-LUNG: A multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line
https://esmocongress.esmo.orgSource: Jordi Remon · x.com